Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
AbbVie clinical trials
The registry lists 2,241 studies whose lead sponsor is AbbVie or one of 25 companies grouped under it. 134 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the AbbVie studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to AbbVie.
- AbbVie967 studiesSame company
Something wrong?
- 505 studies →
- AbbVie (prior sponsor, Abbott)223 studiesSame company
Something wrong?
- 168 studies →
- 58 studies →
- 58 studies →
- 54 studies →
- 39 studies →
- 30 studies →
- 23 studies →
- 22 studies →
- Naurex, Inc, an affiliate of Allergan plc20 studies →Acquired — became part of AbbVie, May 8, 2020 · source ↗
Something wrong?
- 16 studies →
- 12 studies →
- 11 studies →
- Durata Therapeutics Inc., an affiliate of Allergan plc6 studies →Acquired — became part of AbbVie, May 8, 2020 · source ↗
Something wrong?
- 6 studies →
- 4 studies →
- 4 studies →
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc4 studies →Acquired — became part of AbbVie, May 8, 2020 · source ↗
Something wrong?
- 2 studies →
- 2 studies →
- Vitae Pharmaceuticals Inc., an Allergan affiliate2 studies →Acquired — became part of AbbVie, May 8, 2020 · source ↗
Something wrong?
- Pharmacyclics Switzerland GmbH2 studies →Acquired — became part of AbbVie, May 26, 2015 · source ↗
Something wrong?
- 1 study →
- 1 study →
- 1 study →
Focus areas
Conditions AbbVie leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Hepatitis C109Neoplasms95Hepatitis C, Chronic92Ocular Hypertension81Hypertension79Arthritis, Rheumatoid77Psoriasis74Glaucoma73Infections64Glaucoma, Open-Angle59Depression58Crohn Disease56Leukemia, Lymphocytic, Chronic, B-Cell54Depressive Disorder53Depressive Disorder, Major53Colitis, Ulcerative52Migraine Disorders52Dry Eye Syndromes49Parkinson Disease46Leukemia, Myeloid, Acute43Carcinoma, Non-Small-Cell Lung41Multiple Myeloma41Communicable Diseases40Arthritis, Psoriatic36
Show all 82 areas
Keratoconjunctivitis Sicca35Lymphoma35Dermatitis, Atopic34Leiomyoma33Macular Edema32Urinary Bladder, Overactive30Myofibroma29Ulcer28Alzheimer Disease27Lipid Metabolism Disorders27Schizophrenia27Hypogonadism25Kidney Diseases25Lymphoma, Non-Hodgkin25Ovarian Neoplasms25Spondylarthritis25Spondylitis, Ankylosing23Small Cell Lung Carcinoma22Macular Degeneration21Endometriosis20Renal Insufficiency, Chronic20Muscle Spasticity19Neoplasm Metastasis19Hidradenitis Suppurativa18HIV Infections18Cystic Fibrosis17Exocrine Pancreatic Insufficiency17Renal Insufficiency17Retinal Vein Occlusion16Urinary Incontinence16Irritable Bowel Syndrome15Acne Vulgaris14Virus Diseases14Colorectal Neoplasms13Enuresis13Hyperparathyroidism, Secondary13Liver Cirrhosis13Osteoporosis13Alopecia Areata12Carcinoma12Eczema12Fallopian Tube Neoplasms12Kidney Failure, Chronic12Squamous Cell Carcinoma of Head and Neck12Asthma11Bipolar Disorder11Breast Neoplasms11Conjunctivitis11Hypotrichosis11Uveitis11Arthritis, Juvenile10Carcinoma, Ovarian Epithelial10Constipation10Cystitis, Interstitial10Facies10Fibromyalgia10Lymphoma, Large B-Cell, Diffuse10Neuralgia10
Studies
Recruiting first, then most recently updated. Showing 50 of 2,241. Browse all 2,241 →
- Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)RecruitingNCT07007065Phase 3
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia AreataRecruitingNCT07772492Phase 3
- A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic DermatitisRecruitingNCT07003425Phase 2
Sponsor listed in the registry: Apogee Therapeutics, Inc. · First submitted before Apogee Therapeutics, Inc. became part of AbbVie
- A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06568939Phase 2
- Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative ColitisRecruitingNCT06764706
- A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)RecruitingNCT06953960Phase 1/2
- Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential TremorRecruitingNCT07673107Phase 2
- A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)RecruitingNCT07581002Phase 2/3
- A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative ColitisRecruitingNCT07071519Phase 3
- Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life SettingRecruitingNCT03342144
- Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruitingNCT06772623Phase 1/2
- A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.RecruitingNCT06890338Phase 2
- A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT05995353Phase 3
- A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)RecruitingNCT07409246Phase 1
- A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)RecruitingNCT07607964Phase 1
- Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative ColitisRecruitingNCT07697456Phase 2
- Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related ComorbiditiesRecruitingNCT07752979Phase 2
- A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult ParticipantsRecruitingNCT07756645Phase 3
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataRecruitingNCT06012240Phase 3
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT04928846Phase 3
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingNCT06892522Phase 1/2
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerRecruitingNCT06820463Phase 2
- A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingNCT07095452Phase 2/3
- A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal CancerRecruitingNCT07525206Phase 3
- Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin SmoothnessRecruitingNCT07880756Phase 3
- Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular EdemaRecruitingNCT07592273Phase 2/3
- A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingNCT07744126Phase 2
- A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid TumorsRecruitingNCT07807956Phase 1
- A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettINGRecruitingNCT06712628
- Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400RecruitingNCT06084481Phase 1
- A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian CancerRecruitingNCT07278336Phase 1
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerRecruitingNCT07155174Phase 2
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal AdenocarcinomaRecruitingNCT07490301Phase 2/3
- A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerRecruitingNCT07059845Phase 2
- A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary CancersRecruitingNCT07769502Phase 2
- A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial LinesRecruitingNCT07871513Phase 2
- A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With GlaucomaRecruitingNCT06822738Phase 3
- A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 YearsRecruitingNCT06810505Phase 3
- A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of DiseaseRecruitingNCT07023289Phase 2
- A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisRecruitingNCT06972446Phase 2
- Study to Assess Participant Satisfaction After Jawline and Neck TreatmentRecruitingNCT07794891Phase 4
- A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab InjectionsNot yet recruitingNCT07862764
- A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic MigraineRecruitingNCT05711394Phase 3
- A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerRecruitingNCT07005102Phase 2/3
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerRecruitingNCT07155187Phase 2/3
- A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)RecruitingNCT07306832Phase 1
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung CancerNot yet recruitingNCT07821684Phase 3
- A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy AdultsNot yet recruitingNCT07856706Phase 1
- Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)RecruitingNCT06916507
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other TherapiesRecruitingNCT07024784Phase 2